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Abstract
Background: Chorea-acanthocytosis (ChAc) is a neuroacanthocytosis syndrome presenting with severe movement
disorders poorly responsive to drug therapy. Case reports suggest that bilateral deep brain stimulation (DBS) of the
ventro-postero-lateral internal globus pallidus (GPi) may benefit these patients. To explore this issue, the present
multicentre (n=12) retrospective study collected the short and long term outcome of 15 patients who underwent DBS.
Methods: Data were collected in a standardized way 2-6 months preoperatively, 1-5 months (early) and 6 months or
more (late) after surgery at the last follow-up visit (mean follow-up: 29.5 months).
Results: Motor severity, assessed by the Unified Huntington’s Disease Rating Scale-Motor Score, UHDRS-MS), was
significantly reduced at both early and late post-surgery time points (mean improvement 54.3% and 44.1%,
respectively). Functional capacity (UHDRS-Functional Capacity Score) was also significantly improved at both post-
surgery time points (mean 75.5% and 73.3%, respectively), whereas incapacity (UHDRS-Independence Score)
improvement reached significance at early post-surgery only (mean 37.3%). Long term significant improvement of
motor symptom severity (≥20 % from baseline) was observed in 61.5 % of the patients. Chorea and dystonia
improved, whereas effects on dysarthria and swallowing were variable. Parkinsonism did not improve. Linear
regression analysis showed that preoperative motor severity predicted motor improvement at both post-surgery time
points. The most serious adverse event was device infection and cerebral abscess, and one patient died suddenly of
unclear cause, 4 years after surgery.
Conclusion: This study shows that bilateral DBS of the GPi effectively reduces the severity of drug-resistant
hyperkinetic movement disorders such as present in ChAc.
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Introduction
Chorea-acanthocytosis (ChAc) is an autosomal recessive
disease due to mutations of the VPS13A gene encoding for
chorein [1]. It belongs to the neuroacanthocytosis syndromes, a
heterogeneous group of genetically defined conditions,
exhibiting neurological and neuropsychiatric disorders with red
blood cell acanthocytosis [1,2]. ChAc is very rare, and typically
presents as an adult-onset progressive disorder resembling
Huntington's disease (HD) [1,2]. ChAc has however a slower
progression, and displays some more or less specific clinical
features such as tongue- and lip-biting, self-mutilations,
seizures and neuromuscular manifestations but no specific
neuropathological features besides prominent striatal
degeneration [2,3].
There is no specific treatment for ChAc and the most
frequent and disabling motor disorders, chorea and dystonia,
are poorly controlled by conventional symptomatic drug therapy
[2]. This has prompted neurosurgical treatment attempts, such
as stereotactic brain lesions [4,5], and, more recently, deep
brain stimulation (DBS) surgery of the internal globus pallidus
(GPi) [6-8] following reported success in the management of
other hyperkinetic movement disorders [9-12]. However, only
single case or small series have been reported
heterogeneously and in the short term, which likely bias the
results towards favourable outcomes.
We performed a worldwide multicentre retrospective and
cross-sectional study to gather all currently available data on all
ChAc patients treated by GPi DBS and to provide a
standardized, long-term comprehensive review of the clinical
and functional outcome of these patients. In addition, to help
guide GPi DBS surgery decision making in ChAc patients we
aimed at identifying factors corresponding with favourable
outcomes.
Clinical Materials and Methods
A total of 12 centres were contacted to participate in this
retrospective study.
Case selection
Movement disorders and neurosurgical tertiary centres were
identified and contacted on the basis of scientific publications
(original research and review articles published between 1997
and November 2012) in Medline and PubMed databases
(search terms: deep brain stimulation, DBS, high-frequency
stimulation, pallidal stimulation, and neuroacanthocytosis,
chorea, chorea-acanthocytosis, ChAc), as well as of meeting
abstracts. The support association for neuroacanthocytosis
patients (www.naadvocacy.org), and the diagnostic reference
centre and database in Munich, Germany, also collaborated for
patient identification, and announcements were published at
the Movement Disorders Society (MDS) meeting 2011 and
MDS website.
Patients
Selected patients were diagnosed with molecularly proven or
clinically probable ChAc (Table 1), and treated with GPi DBS
regardless of surgery outcome. In the case of previously
published cases, authors were asked to provide additional
updated long term information at last patient visit using a
standardized data collection sheet. Recruitment was conducted
from February 2011 to November 2012.
Data acquisition, protocol and surgery outcome
measures
All centres were sent a standardized data collection sheet,
prepared according to the guidelines for reporting results from
clinical DBS studies in Parkinson’s disease [13].
Data were collected 2-6 months preoperatively (PREOP), at
1-5 months postoperatively (early post-operative: EPOP), and
6 months or more after surgery (last outcome reporting: LOR)
(see Table S1).
Change in the severity of the motor disorder was measured
by the Unified Huntington’s Disease Rating Scale-Motor Score
(UHDRS-MS), and in functional status by the UHDRS-
Independence Score (UHDRS-IS) and the UHDRS-Functional
Capacity Score (UHDRS-FCS) [14]. In accordance with
previous studies [9,15] an improvement equal or superior to
20% of the baseline score was considered as clinically
relevant.
Data analysis
Data obtained are presented as the mean ± SEM values for
each scale administered and at each time point: PREOP,
EPOP and LOR. Statistical analysis was carried out using
Statistica 8.0 for Windows (Statsoft, Maison-Alfort, France).
Data were first analyzed by the Kolmogorov-Smirnov Test for
normal distribution (p > 0.05). Thereafter, the effect of DBS
upon each variable (UHDRS-MS, UHDRS-IS, UHDRS-FCS)
was assessed by a multifactor analysis of variance (ANOVA)
with time as the within-subjects factor. When ANOVA results
were significant (p<0.05), the post hoc Bonferroni test was
applied to allow adequate multiple comparisons between
groups.
For each variable, ANOVA was performed using only those
cases (11 patients) for which values were available at all three
time points (Table 2). Individual values available for each
patient were also entered and plotted at each time point. Data
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available at EPOP and/or LOR time points were also
expressed as the percentage of PREOP values (100%).
A linear regression analysis was performed to identify
preoperative factors (age at surgery, disease duration and
severity) that could predict DBS-induced improvement of motor
and/or functional impairment at EPOP and/or LOR
assessments. Analysis was performed using cases for which
postoperative UHDRS values were available at either EPOP
and/or LOR evaluations (see Table 2). “Improvement” was
considered for each patient as the difference between UHDRS
scores at PREOP and EPOP or LOR time points. P-values <
0.05 were considered significant; no adjustment was made for
multiple testing.
Ethics
The study was conducted after approval from the local Ethics
Committee of the University Hospital of Bordeaux, and was
carried out in accordance with the ethical standards laid down
in the 1964 Declaration of Helsinki. All patients or a family
member gave their written informed consent prior to their
inclusion in the study, and data were entered into a database in
an anonymous format in accordance with the personal data
protection laws in France (CNIL).
Results
Eleven out of the 12 centres (see Appendix S1) provided
data. Fifteen patients were included in the data analysis but
data for one patient (patient 11) were extracted only from a
previous publication, and UHDRS scores were missing. Table
2 indicates the number of patients available for analysis at
each time point. Twelve of the 15 cases have already been
published in either scientific article format (n=9) or in congress
posters (n=3) (for individual references see Table 3).
Table 1. Basic diagnostic data in 15 patients with chorea.
Patient Acanthocytes (%) CK* Chorein in Western blot of red cells membranes VPS13A mutations MRI (atrophy)
1 20 x4 absent ND Ca, Pu, Cx
2 40 x4 absent ND Ca
3 10 ND present (2 blots in 4 years) present, o.m. Ca
4 ↑ x2.6 absent present, c.h. nl
5 25 x1.1 absent present, H Ca, Pu, Cx; striatal T2 hyper-intensity
6 31 x2.1 absent present, H Ca, Cx
7 ND ND ND present, c.h. nl
8 20 x1.6 ND present, c.h. Ca heads, Pu with T2 hyper-intensity
9 10 x18.8 ND present, H nl
10 ↑ ND subnormal low expression ND nl
11 20 x4.2 ND present, c.h. Ca heads, subcortical.
12 ↑ ND absent ND Ca heads, Pu T2 hyper-intensity
13 7 x13.2 absent ND Ca, lentiform nuclei with T2 hyper-intensity
14 6 x2.2 ND ND Ca, Pu, T2 hyper-intensity
15 6 ND ND ND Ca, Pu, T2 hyper-intensity
CK = creatine kinase; ↑ elevated; * relative increase with respect to normal value for each centre laboratory; o.m. = one mutation known; c.h. = compound heterozygous; H =
homozygous; Ca = Caudate; Cx = Cortical; Pu = Putamen; nl = normal; ND = not done.
doi: 10.1371/journal.pone.0079241.t001
Table 2. Number of patients with exploitable data.
 PREOP EPOP LOR
UHDRS-MS 13 13 11
UHDRS-FCS 14 14 11
UHDRS-IS 14 14 11
BFMDRS 1 1 1
MMSE 9 7 3
Adverse events NA 15 15
Clinical status/outcome by symptoms 15 14 14
Drug treatment 14 - 14
PREOP: preoperative; EPOP: early post-operative; LOR: last outcome report; UHDRS-MS: Unified Huntington’s Disease Rating Scale-Motor Score; UHDRS-FCS: UHDRS-
Functional-Capacity Score; UHDRS-IS: UHDRS-Independence Score; BFMDRS-M: Burke-Fahn-Marsden Dystonia Rating Scale-Motor part [16]; MMSE: Mini Mental State
Examination [17]; NA: not applicable.
doi: 10.1371/journal.pone.0079241.t002
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Patient clinical features
Patient characteristics are summarized in Table 3. Most of
the patients presented with chorea (n=14, 93%) and/or
dystonia (n=12, 80%), frequently associated with trunk spasms
(n=12, 80%) and/or head drops/chorea (n=10, 67%), leading to
recurrent face and head trauma. Most patients had gait and
balance impairment. All patients had dysarthria, severe in 6.
Orofacial dyskinesias and tics were present in 12 patients, 10
displayed lip-, tongue- or cheek-biting. Swallowing problems
were present in 12 patients. Five patients had epilepsy,
effectively treated in all. Psychiatric and behavioural
disturbances, mainly depression and obsessive-compulsive
behaviour, were present in 11 patients. Cognition was reported
as slightly impaired in 6 patients, but extensive
neuropsychological evaluations were lacking.
Surgery was indicated to reduce disabling motor symptoms
such as chorea, dystonia, trunk spasms, falls, gait impairment
(7 patients), self-mutilating and biting behaviours (6 patients) or
head banging induced by trunk spasms or head drops (4
patients), feeding dystonia (3 patients) and recurrent belching
(2 patients).
Outcome measures of global efficacy
Figure 1 displays the effect of DBS on UHDRS motor scores
at EPOP and LOR time points compared to baseline. Mean
UHDRS-MS (Figure 1A) was significantly reduced at both time
points after surgery. Mean proportional improvement of
UHDRS-MS compared to baseline was +54.3% and +44.1% for
EPOP and LOR, respectively. Figures 1B and 1C show
individual outcomes on UHDRS-MS scores and changes
compared to PREOP values. All 13 patients showed an
improvement of 20% or more at EPOP, whereas at LOR, only 8
of these 13 patients (61.5 %), for whom UHDRS-MS was
available, showed a significant improvement.
DBS effects on the patients’ functional status, as evaluated
by UHDRS-IS and UHDRS-FCS, are displayed in Figure 2.
Mean UHDRS-IS was improved at both time points after
surgery (EPOP: +37.3%, LOR: +22%), but reached
significance only at EPOP (Figure 2A). Ten out of 14 patients
(71.4 %) for whom UHDRS-IS was available at EPOP showed
a significant improvement, which was still observed at LOR for
6 of them (Figure 2B, 2C). Mean UHDRS-FCS was significantly
improved at both time points post-surgery (EPOP: +75.5%;
LOR: +73.3%; Figure 2D). Eleven out of 14 patients (78.6 %)
for whom UHDRS-IS was available at EPOP showed a
clinically relevant improvement; which was still observed at
LOR for 6 of them (Figure 2E, 2F).
Outcome by symptoms
Chorea and dystonia were the most improved symptoms in a
majority of patients. In terms of chorea, 13 out of 14 patients
were improved at EPOP, observed within hours or days after
surgery. At LOR, some relapse of choreic movements was
observed in 3 patients (1, 4 and 15 at 24, 11 and 21 months,
respectively), while the effect was maintained in others. Trunk
spasms improvement was marked and maximal at EPOP for
Table 3. Patient characteristics.
Patient number Gender
Age at onset of
symptoms (years)
Age at time of diagnosis
(years)
Age at surgery
(years)
Duration of disease
(years)
LOR after surgery
(months)
1 [18] F 25 26 33 8 60
2 F 31 34 38 7 36
3 F 35 37 41 6 36
4 [19,20] M 48 49 49 1 41
5 [21] M 29 46 48 19 24
6 [21] M 30 32 32 2 36
7 [22] M 22 24 31 9 39
8 [23] F 35 38 39 4 13
9 [24,25] M 24 29 32 8 84
10 F 25 29 32 7 6
11 [26] M 35 38 38 3 NA*
12 [8] M 30 45 54 24 5
13 [8] M 32 39 43 11 3
14 [7] M 17 40 40 23 9
15 [7] M 18 30 30 12 21
Mean ± SD 5 F (33%) 10 M(67%) 29.1 ± 7.8 35.7 ± 7.5 38.7 ± 7.3 9.6 ± 7.2 29.5 ± 23
F = female, M = male; LOR = last outcome report; NA = not available; * electrodes were removed 3 weeks after surgery.
doi: 10.1371/journal.pone.0079241.t003
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Figure 1.  Effect of deep brain stimulation on motor
impairment as assessed by the Unified Huntington’s
Disease Rating Scale-Motor Score (UHDRS-MS).  Bar
histograms (panel A) represent means ± SEM (n= 11 patients).
Line plots (panels B, C) show individual values per patient
plotted at each of three time points: 2-6 months preoperatively
(PREOP), 1-5 months postoperatively (early post-operative:
EPOP), and 6 months or more after surgery (last outcome
reporting: LOR). Individual data curves are shown in panel B,
whereas panel C depicts percentage changes at EPOP and
LOR with PREOP values set to 100% to make improvements
and deteriorations easier to distinguish. Scores of patient 7
correspond to the Burke-Fahn-Marsden Dystonia Rating Scale-
Motor part (BFMDRS-M) [16]. **p<0.01, ***p<0.001 versus
PREOP time point (Bonferroni test after ANOVA: F(2, 20)= 15.11,
p< 0.001, n= 11).
doi: 10.1371/journal.pone.0079241.g001
11 out of 12 patients. Patients 3 and 9 experienced slower
improvement of limb dystonia, with the maximum effect
observed at LOR.
There was improvement of gait in patients with chorea and
dystonia, but this was not significant in patients with pre-
operative parkinsonism (4 out of 6). Except for patient 15, all
patients who suffered from orofacial movements and self-
mutilation improved. DBS had little effect on dysarthria, only 2
improved at EPOP, one of whom was found worse at LOR; one
patient (patient 9) presented complete anarthria after surgery
which improved after withdrawal of stimulation. Feeding status
was available at LOR only in 9 patients and 6 had improved.
Insufficient information was available to allow conclusions upon
cognitive or neuropsychiatric and behavioural disorders. Mini
Mental State Examination [17] was available in 9 patients
before surgery (mean score = 26.8; range = 19-30), in 7
patients at EPOP (mean score = 27.3; range = 25-30), and in 3
patients at LOR (mean score = 26.7; range = 26-27). After
surgery, antidepressant treatment remained unchanged in 6
patients. Mood improved for 3 patients, but no change was
reported for the others. Four patients (patients 2, 7, 10 and 11)
had preoperative compulsive behaviours: after surgery a
marked and sustained (48 months) improvement was observed
in one patient (patient 7).
Relationship between preoperative status and surgery
outcome
No significant relationship was found between age at surgery
or disease duration and postoperative improvement on either
motor or functional scales. Preoperative motor severity in
UHDRS-MS predicted improvement in motor function at both
EPOP (Figure 3A) and LOR time points (Figure 3B). Motor
improvement was associated with an improvement in functional
status (UHDRS-FCS) at EPOP and at LOR (Figure 3C, D); but
not in the dependency score at both time points (UHDRS-IS).
Surgery: implantation, target coordinates and
stimulation parameters
Surgical procedure details and individual electrode
coordinates as per the Schaltenbrand and Wahren atlas [27]
are reported in Tables S2 and S3, respectively. Mean and
range of stimulation parameters at per-operative, EPOP and
LOR assessments are displayed in Table 4; individual optimal
stimulation settings are given in Supporting Information, Table
S4.
The pulse frequency applied at EPOP was high in 10
patients (130-185 Hz), and low in 4 (40-60 Hz). Stimulus
duration, frequency and amplitude tended to increase at LOR.
No patient initially treated with high frequency was switched to
low frequency for further improvement; only one patient initially
treated with low frequency was switched to high frequency
stimulation at LOR (patient 9). At EPOP, stimulation was single
monopolar for 10 patients and double monopolar for 4 patients.
Most patients were treated via ventral contacts. At LOR, the
stimulation field tended to be larger and more dorsal, 4 patients
were still stimulated by single monopolar contact, and 6 by
double or triple monopolar contacts.
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Figure 2.  Effect of deep brain stimulation on independence and functional impairment as assessed by the Unified
Huntington’s Disease Rating Scale-Independence Score (UHDRS-IS) and UHDRS-Functional Capacity Score (UHDRS-FCS),
respectively.  Bar histograms (panels A, D) represent means ± SEM (n= 11 patients). Line plots (panels B, C, E, F) show individual
values per patient plotted at each of three time points: 2-6 months preoperatively (PREOP), 1-5 months postoperatively (early post-
operative: EPOP), and 6 months or more after surgery (last outcome reporting: LOR). Individual data curves are shown in panels B
and E, whereas panels C and F depict percentage changes at EPOP and LOR with PREOP values set to 100% to make
improvements and deteriorations easier to distinguish. *p<0.05 versus the corresponding PREOP time point (Bonferroni test after
ANOVA: F(2, 20)= 4.72, p< 0.05, n= 11, and F(2, 20)= 5.94, p< 0.01, n= 11, for UHDRS-IS and UHDRS-FCS, respectively).
doi: 10.1371/journal.pone.0079241.g002
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Movement disorders medication
Before surgery, all patients took at least one drug for their
movement disorder (neuroleptics, tetrabenazine,
benzodiazepines, amantadine, anticholinergic drugs (mean
number taken: 3 ± 1, mean number tried: 4 ± 2). At LOR,
medication was reduced in 7 patients (50%) and had remained
unchanged in 3 patients (21%), but drug number had increased
in 4 patients (28.6%). In only one patient (patient 9) medication
was discontinued for 2 years after surgery.
DBS adverse events
Data on adverse events were available for all 15 patients.
Surgery-related adverse events.  Patient 9 had a
misplaced right electrode requiring a new surgery. Two months
after surgery, patient 13 had a device infection leading to
implanted pulse generator (IPG) removal, thereby causing
severe rebound of abnormal movements requiring sedation in
the intensive care unit. Ten days later, while the infection was
apparently resolved, a new IPG was implanted but
Figure 3.  Regression analysis between preoperative (PREOP) severity of motor impairment, as assessed by the Unified
Huntington’s Disease Rating Scale-Motor Score (UHDRS-MS), and motor severity improvement at early and late post-
operative time points (EPOP, panel A, r = 0.66, r2 = 0.44, p< 0.05, n=13; LOR, panel B, r = 0.67, r2 = 0.45, p< 0.05, n=11); and
motor severity improvement versus functional improvement, as assessed by the UHDRS-Functional Capacity Score
(UHDRS-FCS), at EPOP (panel C, r = 0.63, r2 = 0.40, p< 0.05, n=13) and LOR (panel D, r = 0.67, r2 = 0.45, p< 0.05, n=11) time
points.  For each patient, motor and functional improvements correspond to the difference between appropriate UHDRS scores at
PREOP and EPOP or LOR time points.
doi: 10.1371/journal.pone.0079241.g003
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subsequently the patient developed a cerebral abscess at the
sites of the left electrode tracks, which prompted the complete
removal of the whole system. One year later, a new right GPi
DBS has had a positive effect on left-sided symptoms.
Stimulation-related adverse events.  Patient 1 displayed a
worsening of trunk spasms at 40-50Hz stimulation frequency
and with the use of the ventral contact he experienced gait
freezing that disappeared with stimulation at more dorsal
contacts but at the cost of worsening hyperkinesias and trunk
spasms. Patient 4, at EPOP period, complained of abnormal
face and mouth pulling over 60 Hz stimulation. One month after
surgery he displayed increased tongue movements at 50Hz
stimulation using bilateral double monopolar settings (C+1-2-),
thereby requiring an adjustment towards bilateral single
monopolar (C+1-) stimulation. Patient 9, at EPOP time point,
exhibited worsening of chorea and dysarthria, with palilalia and
drooling at 130Hz, 40Hz stimulation was effective on choreic
movements. At LOR assessment, again under 130Hz
stimulation, abnormal movements were well-controlled but
clinical examination revealed mild parkinsonism and complete
anarthria. Rigidity and bradykinesia slightly decreased 2 hours
after stopping the stimulation, and the patient was able to
pronounce few simple words. Patient 11 experienced increased
chorea and side effects (facial hemispasm, visual disturbances
and vegetative changes) whatever the bipolar stimulation
parameters used at high frequency. Low frequency stimulation
led to deterioration of speech and gait [26]. Patient 14 had an
exacerbation of both chorea and dystonia at high-frequency
(130 Hz) stimulation. Patient 15 complained of blurred vision
during the per-operative macro-stimulation on the lowest plots
and using high amplitude.
Device-related adverse events.  Two years after surgery,
patient 2 experienced a “Twiddler syndrome” with lead rupture
that required the replacement of the extension wires, IPG and
both electrodes [28]. Device infection in patient 13 was
discussed above.
Patient-related adverse events.  At LOR, patient 4
requested to have the stimulator switched “off” because of
suspected stimulation-related increased involuntary tongue
protrusion. This, however, resulted in a further increase of
tongue thrusting and DBS subsequently was again turned “on”,
with settings unchanged. This patient suddenly died at home at
age 53, 4 years after surgery and 1 year after LOR. An autopsy
was not performed and the cause of death remained
undetermined.
Table 4. Mean stimulation parameters.
Parameter intra-OP (n=14) EPOP (n=14) LOR (n=12)
Pulse frequency (Hz) 102.5 (40-185) 114.3 (40-185) 128.8 (40-185)
Pulse width (μs) 90.0 (60-210) 96.3 (60-180) 104.0 (60-150)
Pulse amplitude (V) 2.8 (1.6-4.5) 2.9 (2-4.5) 3.4 (2-4.8)
Data= mean (range); intra-OP= intra-operative; EPOP= early post-operative; LOR=
last outcome report.
doi: 10.1371/journal.pone.0079241.t004
Discussion
The present long-term multicentre study of 15 cases of ChAc
treated with bilateral DBS of the GPi provides evidence that
stimulation of the postero-ventrolateral "sensorimotor" portion
of the GPi may help to manage severe, drug-resistant
movement disorders, particularly chorea and dystonia. In the
11 patients, with two postoperative standardized evaluations, a
significant long term improvement of motor symptom severity
(improvement ≥ 20% in UHDRS-MS) was observed for 61.5 %
at a mean follow-up of 2.5 years. Because duration of follow-up
was variable, we constructed individual outcome curves that
demonstrated that most patients remained above the pre-
operative level, even though there was a tendency for motor
deterioration over time. Gait impairment, orofacial movements
and tics, self-mutilation, head drops and trunk spasms were
DBS-sensitive symptoms, while dysarthria and feeding
problems were less DBS-responsive and had a more variable
outcome. Limb, face and trunk chorea improved early after
surgery and responded immediately to switching the
stimulation “on” and relapsed abruptly when switching “off”.
This response resembles that observed in HD [10,29,30] and in
McLeod Syndrome [5,25].
An early improvement was observed for phasic/mobile
dystonia (debilitating trunk and limb spasms, head drops with
injuries), as described in other conditions including primary
generalized dystonia (PGD) [11,31,32]. Conversely,
improvement of tonic dystonia was slower and occurred after 6
months of stimulation for patients 3 and 9, also resembling
observations made in PGD [31,33].
As in other primary choreic syndromes [10,29] we observed
a tendency for symptom deterioration and/or occurrence of
parkinsonism in the longer term. This may be related to
disease progression and/or to DBS itself, possibly by activation
of inhibitory pallidal outputs to the motor thalamus [34].
Although GPi-DBS is an effective treatment for motor
symptoms in Parkinson’s disease (PD), worsening of akinesia
and gate deterioration was also observed in GPi-DBS-treated
PD patients depending on the stimulated area within the GPi
[34].
Dysarthria occurrence or worsening could also be related to
disease progression or to DBS adverse effect, as observed in
one of our patients (patient 9). GPi-DBS efficacy on swallowing
was highly variable. Improvement could be seen when
swallowing impairment was mainly due to feeding dystonia,
orolingual movement disorders or trunk spasms. Otherwise,
swallowing problems tended to deteriorate along with axial
signs and parkinsonism.
At LOR assessment, drugs used to control the movement
disorders were reduced in 71% of patients (10/14), thus
supporting the assumption that the effect upon movement
disorders can reasonably be attributed to DBS rather than to
drug regime changes. Only one patient did not benefit from
strictly monopolar DBS. His disease was very advanced (17
years disease duration) as well as drug-resistant (11 drugs had
been tried).
Motor improvement translated into an improvement of
functional capacity both at early and late post-operative
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observations. The patients showed significant functional
improvement of 75.5% (UHDRS-FCS) at EPOP and LOR.
Independence, as assessed by the UHDRS-IS, was
significantly improved only at EPOP, even if there was also a
trend for improvement at LOR. Thus, improvement in motor
signs and functional capacity did not fully translate to
improvement of dependency at the long-term. This could be
due to the sensitivity and/or the psychometric characteristics of
the subscale used and/or the low number of patients under
study. Alternatively, DBS, while improving motor symptoms and
function, may be ineffective with respect to dependency in
patients severely affected by advanced disease. This issue
remains to be addressed in prospective studies using also
quality of life measures. The cognitive outcome of ChAc
patients with GPi DBS was inconclusive with the limited data in
hand.
There was no correlation between the patients´
demographics or disease duration and outcome. However,
there was a significant relation between pre-operative severity
of motor signs (UHDRS-MS) and improvement of motor signs.
The UHDRS scale was used as previously proposed for
neurodegeneration with brain iron accumulation (NBIA) in an
attempt to standardize the data available [15] but, as in NBIA,
the UHDRS has not been validated in ChAc. Although the
disease spectrum is very similar to HD, the scale may have
missed characteristic ChAc symptoms such as orofacial
movement disorders and self-mutilations, feeding dystonia,
trunk spasms, head drops, breathing dystonia and recurrent
belching. Formal validation of the UHDRS in ChAc or design of
a ChAc specific scale is needed but difficult to perform due to
the very small number of patients involved.
Implanted devices and stimulation parameter settings varied
among centres. However, optimal stimulation parameter
settings mostly used higher frequency (mean = 102.5 Hz) and
monopolar stimulation of lower contacts with a mean amplitude
of 2.8 volts. There was a tendency to gradually increase
frequency and amplitude along with the use of more dorsal
contacts at the latest follow-up [35,36]. This may be due to
disease progression or, alternatively, to an attempt to control
increased bradykinesia over time [37].
The risk/benefit ratio appears acceptable in the present case
series. Although the limited number of patients prevents
definitive conclusions, adverse events were roughly similar to
those observed in HD, PD, NBIA or dystonia case series
[10,15,30,31,38,39]. Misplacement of one electrode requiring
new surgery, Twiddler syndrome and device infection with
brain abscess were the most serious surgery-related adverse
events. In the 5 patients with preoperative epilepsy, there was
no worsening of epilepsy or increase in antiepileptic drug
dosage, and no de novo seizures after surgery in patients
without epilepsy. These findings, although observed in few
patients, suggest that epilepsy may not be a contraindication or
a serious concern for GPi-DBS in ChAc, but further studies are
needed to address this point. Indeed, a recent case reported
possible intraoperative seizures and also post-operative
intracranial hematoma in a 32-years-old patient with non-
molecularly proven ChAc [40]. Two years later, the patient
underwent a second DBS operation leading to a marked
improvement of his dystonia, chorea and overall quality of life 2
and 8 months postoperatively [40].
Finally, although our results are positive and encouraging, it
is important to note that our study presents some limitations
due to its retrospective and multi-centre nature leading to some
lack of homogeneity in patients’ assessment and data
collection, despite of our efforts of standardization. Also, some
data were missing (see Table 2), and in two patients (Table 1,
patients 14 and 15) the diagnosis of ChAc was only “highly
probable” in the absence of screening for Chorein blot or
VPS13A mutations [7].
In conclusion, our study of 15 patients collected worldwide, is
in favour of long-term efficacy and relative safety of the bilateral
GPi-DBS for severe, drug-resistant hyperkinetic movement
disorders (chorea, dystonia and/or orofacial movements and
self-mutilations) in ChAc. DBS provides long-term motor and
functional improvement but has less effect on long-term
dependency. Also, as reported previously in NBIA patients [15]
preoperative severity is predictive of a good response to
bilateral GPi-DBS. Our study emphasizes the need to improve
prospective data collection in international frameworks;
gathering clinical characteristics of ChAc patients and their long
term monitoring is essential to further evaluate interventions
such as DBS in this debilitating disease.
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